UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
__________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~September~~October 293, 2017

PROTEA BIOSCIENCES GROUP, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-51474		20-2903252
(State or Other Jurisdiction of Incorporation)	(Commission File Number)		(IRS Employer Identification No.)

	1311 Pineview Drive, Suite 501 Morgantown, WV 26505
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code:		(304) 292-2226
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2)

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

~~Forward-Looking~~Item ~~Statements~~5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~The~~On ~~Presentation~~October ~~(as defined below) contains forward-looking statements within the meaning of the federal securities laws. Any statements that express or involve discussions with respect to predictions~~3, ~~expectations~~2017, ~~beliefs,~~the ~~plans,~~Board ~~projections, objectives, and goals, assumption~~ of ~~future events or performance~~Directors ~~are~~(the ~~not statements of historical fact and may be deemed~~ “~~forward-looking statements.~~Board” ~~Forward-looking~~) ~~statements can often be identified by the use~~ of ~~words~~Protea ~~such~~Biosciences ~~as “may~~Group,” ~~“will~~Inc.,” ~~“estimate,”~~a ~~“intend,” “continue,”~~Delaware ~~“believe,”~~corporation ~~“expect,”~~(the “~~plan,~~Company” ~~“propose,” “projected,”~~) ~~“seek,”~~accepted ~~or “anticipate,” although not all forward-looking statements contain these or other identifying words. Forward-looking statements are based on expectations, estimates and projections at~~ the ~~time~~resignation ~~the~~of ~~statements~~Steve ~~are~~Anoline ~~made that involve~~ a ~~number~~member of ~~risks~~the ~~and~~Board. ~~uncertainties which could cause actual results or events to differ materially from those presently anticipated~~Mr. ~~Such~~Anoline ~~forward-looking~~resigned ~~statements relate to, among other things: expected revenue, cash flow and earnings growth; strategies and timelines~~ for ~~growth~~personal of the Company’s business; and projected capital expenditures. These statements are qualified by important factors that could cause the Company’s actual results to differ materially from those reflected by the forward-looking statements. Such factors includereasons, but are not limited to: the Company’s ability to expand its customer base; fluctuations on consumer spending on the Company’s products; difficulties in developing the Company’s technology platform and ~~its ability~~there towas ~~retain~~no ~~key personnel; possible insufficient cash flows and resulting illiquidity; government regulations; stock volatility~~dispute ~~and illiquidity; the Company’s potential failure~~ or ~~inability~~disagreement tobetween ~~implement fully its business plans or strategies; general economic conditions; and the risks and factors described from time to time in the Company’s offerings, reports and filings with the U~~Mr.S. ~~Securities~~Anoline and ~~Exchange Commission (~~the ~~“SEC”). The~~ Company ~~cautions readers not to place undue reliance on any forward-looking statements~~. ~~The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.~~

~~No Offer or Solicitation to Sell~~SIGNATURE

~~This~~Pursuant ~~Report and its exhibits shall not constitute an offer~~ to ~~sell or~~ the ~~solicitation~~ requirements of anthe ~~offer~~Securities toExchange ~~buy,~~Act ~~nor shall there be any sale~~ of ~~securities in any jurisdiction in which such offer~~1934, ~~solicitation~~the orregistrant ~~sale~~has ~~would~~duly becaused ~~unlawful~~this ~~prior~~report to ~~registration~~be orsigned ~~qualification~~on ~~under~~its ~~the~~behalf ~~securities laws of any such jurisdiction. No offering of securities shall be made except~~ by ~~means of a prospectus meeting~~ the ~~requirements~~undersigned ofhereunto ~~Section~~duly ~~10 of the Securities Act~~authorized.

Item 7.01 Regulation FD Disclosure

Dated: October 4, 2017

	PROTEA BIOSCIENCES GROUP, INC.


	By:	/s/ Stephen Turner
		Stephen Turner
		Chief Executive Officer

Protea Biosciences Group, Inc. (“PRGB” or the “Company”) intends to publish on its website and to furnish to investors an investor presentation dated September 2017 (the “Presentation”). A copy of the Presentation is furnished herewith as Exhibit 99.1.

The information furnished in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form 8-K (this “Report”) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit is filed with this Report:

Exhibit No.		Description
99.1		Investor Presentation, dated September 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 29, 2017	PROTEA BIOSCIENCES GROUP, INC.
	By:	/s/ Stephen Turner
		Stephen Turner
		Chief Executive Officer

Filing Compare · Protea Biosciences Group, Inc.